Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03850483 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 344
- Enrollment target
NCT03850483 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 344 participants.
The verdict
NCT03850483, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 344 participants
- Enrollment target
Study Summary
This is a Phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter study in participants with mild to moderate plaque psoriasis. The duration of study participation will be approximately 22 weeks, including up to a 6 week screening period, 12 week treatment period, and approximately 4 week follow up period. Approximately 280 participants are planned to be randomized into the study.
Interventions
- DRUG Vehicle (Placebo)
- DRUG PF-06700841
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2019-04-08 |
| Est. Completion | 2021-04-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03850483
The ClinicalTrials.gov registry entry for NCT03850483 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 344 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle (Placebo) is the first listed.
NCT03850483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03850483 about?
NCT03850483 is a clinical study titled "Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis". This is a Phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter study in participants with mild to moderate plaque psoriasis. The duration of study participation will be approximately 22 weeks, including up to a 6 week screening period, 12 week treatment period, and app...
What is the current status of trial NCT03850483?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 344 participants. The study started on 2019-04-08. Estimated completion is 2021-04-20.
What interventions are being tested in trial NCT03850483?
The interventions under investigation include: Vehicle (Placebo) (DRUG), PF-06700841 (DRUG).
Who is sponsoring clinical trial NCT03850483?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.